favezelimab,pembrolizumab
merck,i-mab
['hodgkin', 'favezelimab', 'lymphoma', 'pembro', 'imab ']
pembrolizumab plus favezelimab in refractory hodgkin lymphoma. n= 34, prior sct 74%, and 50% prior pd1 therapy. orr 29%, cr 9%. mdor 21.9 months. modest activity of this combination. new therapeutic agents are needed for pd1 refractory patients. #ash22 